Exscientia to collaborate with Sanofi for EUR250mil multiple-product development
Exscientia has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease.
List view / Grid view
An assay is an analytical procedure in laboratory medicine, pharmacology and molecular biology for measuring the activity of a target entity.
Exscientia has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease.
GSK's top investigators explain why the data quality offered by Fluorescence lifetime detection technology for drug discovery applications is superior…
3 April 2017 | By Charles River
This webinar reviews standard neuropathic pain models and readouts and will include fine motor kinematic analysis to highlight gait changes...
The IntelliCyt Cy-Clone™ PLUS Assay System will accelerate and improve the quality of clone ranking and selection for developing cell lines which can reduce production costs of biopharmaceuticals...
28 March 2017 | By Charles River
Discover how their multidisciplinary approach to hit ID, design and synthesis of novel chemical templates and development of targeted in vitro and in vivo assays resulted in the nomination of the first development candidate in just over two years...
The Custom Assay Development (CAD) program at DiscoverX develops tailor-made cell lines optimised for your needs, enabling you to jump start your drug discovery programs...
The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research UK.
Dr Sheraz Gul, Head of Assay Development and Screening at the Fraunhofer Institute for Molecular Biology and Applied Ecology, answers questions on assay procedures...
HTS can be carried out in a number of formats, ranging from simple biochemical (target-based) to whole animal screening assay formats. Horst Flotow, from Hit Discovery Constance, discusses the benefits and practicalities of, and recent progress in, whole animal screening. Madhu Lal-Nag, National Center for Advancing Translational Sciences, and Anton…
10 March 2017 | By Charles River
This webinar discusses our newly validated acute and inflammatory in vivo pain models, including information on how they were validated and how they can be used to test new pain treatment compounds, eventually leading to clinical translation...
Included in this issue: Importance of building patient trust; Vaccines & Immunology; Oncology; Assays; Biomarkers; and Antibodies...
High throughput screening (HTS) has become an integral and productive part of early-stage drug discovery, delivering hits that were the starting points for hit-to-lead programmes and resulting in a number of marketed drugs. HTS can be carried out in a number of formats, ranging from simple biochemical (target-based) to whole…
Flow cytometry is a laser-based technology – a powerful tool for drug discovery and the screening process and can be used in all settings, including research, clinical, pharmaceutical and biotechnology. The increasing capabilities of flow cytometers make their incorporation into drug development and screening optimal...
Monitoring cellular drug permeability and target engagement enables assessment of compound efficacy and confirmation of mode of action. InCELL Pulse target engagement assays provide the ability to confirm compound cell entry and target engagement while overcoming limitations of current target engagement assays...
Cell2Sphere is the first simple 3D tissue culture kit for labs interested in more accurate, scalable and dynamic experimental research.